Changes in Gut Microbiota of Patients with Atopic Dermatitis During Balneotherapy

• Published in: Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2022-01, Vol.15, p.163-176
• Main Authors: Thirion, Florence, Guilly, Susie, Fromentin, Sébastien, Plaza Oñate, Florian, Alvarez, Anne-Sophie, Le Chatelier, Emmanuelle, Pons, Nicolas, Levenez, Florence, Quinquis, Benoît, Ehrlich, Stanislav, Doré, Joel, Martin, Richard, Seité, Sophie
• Format: Article
• Language: English
• Subjects: Advertising executives; Atopic dermatitis; balneotherapy; Care and treatment; Dermatitis; Disease; Eczema; GABA; Genes; Gram-positive bacteria; gut microbiota; Life Sciences; Medical research; Medicine, Experimental; Microbiota; Microbiota (Symbiotic organisms); Original Research; Patients; Pruritus; Psoriasis; Quality control; shotgun metagenomics; Skin; Software; Taxonomy; thermal spring water; Tryptophan
• ISSN: 1178-7015; 1178-7015
• DOI: 10.2147/CCID.S342104

Balneotherapy (BT) is the treatment of disease through the use of thermal spring water (TSW). It has been used for centuries and remains a popular form of treatment for dermatologic diseases such as atopic dermatitis (AD). Recent findings highlighted the role of the gut microbiota in AD and the possible crosstalk between gut and skin microbiomes in this pathology. Nevertheless, changes in the composition of the gut microbiota after balneotherapy remain to be elucidated. A total of 96 patients, with moderate to severe AD according to the SCORAD, were enrolled. Stool samples were collected prior and post a 3-week balneotherapy at the thermal care center of La Roche-Posay (France). Composition of the gut microbiota was assessed by shotgun metagenomic sequencing. Species associated with high gut microbiota richness tended to correlate negatively with disease severity (SCORAD) and positively with SCORAD reduction, while species associated with low richness displayed the opposite pattern. Relative abundance of 23 species was significantly altered during BT, these changes being significantly associated with SCORAD reduction during BT, suggesting that gut microbiota composition and AD progression were associated through the treatment. Microbial functions related to gut-brain axis such as GABA and tryptophan metabolism were also altered by the treatment. Long-standing AD patients exhibited a better gut microbial profile than recently diagnosed patients, with higher MSP richness and species associated with SCORAD reduction. In patients with AD, clinical disease parameters such as SCORAD or disease duration are intricately linked to the gut microbiota composition. SCORAD reduction occurring during BT was also associated with gut microbiota. The gut-brain-skin axis via neurotransmitter such as GABA should be further studied in diseases such as AD.